Home Cart Sign in  
Chemical Structure| 1527473-33-1 Chemical Structure| 1527473-33-1

Structure of PF-06447475
CAS No.: 1527473-33-1

Chemical Structure| 1527473-33-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

PF-06447475 is a brain-penetrant, potent and selective LRRK2 inhibitor with IC50 values of 3 nM, possessing neuroprotective activity.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of PF-06447475

CAS No. :1527473-33-1
Formula : C17H15N5O
M.W : 305.33
SMILES Code : N#CC1=CC=CC(C2=CNC3=NC=NC(N4CCOCC4)=C32)=C1
MDL No. :MFCD28347838
InChI Key :BHTWDJBVZQBRKP-UHFFFAOYSA-N
Pubchem ID :72706840

Safety of PF-06447475

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • LRRK2

    LRRK2, IC50:3nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Midbrain dopaminergic neurons 30 nM 14 days To test the effect of LRRK2 inhibitors on α-synuclein pathology in dopaminergic neurons, no significant changes were observed Acta Neuropathol Commun. 2018 May 31;6(1):45
Primary mouse hippocampal neurons 30 nM 18 days Inhibition of LRRK2 kinase activity, significantly reducing the formation of α-synuclein inclusions in G2019S-LRRK2-expressing neurons J Neurosci. 2016 Jul 13;36(28):7415-27
Differentiated SHSY5Y cells 1 and 3 µM 2 hours To evaluate the effect of PF-475 on MPTP-induced LRRK2 phosphorylation. Results showed that PF-475 significantly reduced p-Ser935 levels in a concentration-dependent manner. iScience. 2024 Sep 16;27(10):110980
Mouse embryonic fibroblasts (MEFs) 150 nM 2 hours To evaluate the effect of LRRK2 kinase inhibitors on early stages of autophagy, results showed that PF-06447475 treatment did not affect WIPI2 puncta formation Cell Death Dis. 2023 Jul 15;14(7):436
SH-SY5Y cells 150 nM 2 hours To evaluate the effect of LRRK2 kinase inhibitors on autophagy, results showed that PF-06447475 treatment did not affect autophagy Cell Death Dis. 2023 Jul 15;14(7):436
Hippocampal neurons 5, 30, 120 nM 21 days To test the effect of LRRK2 inhibitors on α-synuclein pathology, found that even robust LRRK2 inhibition is insufficient to reduce α-synuclein pathology Acta Neuropathol Commun. 2018 May 31;6(1):45
RAW264.7 cells 1 and 10 µM 24, 48 and 72 hours Tested the ability of PROTACs to degrade LRRK2, results showed PROTACs did not significantly reduce LRRK2 protein levels ChemMedChem. 2021 Mar 18;16(6):959-965
WT PSEN1 DALNs 1 µM 4 days PF-475 reduced basal levels of accumulated iAβ (-47%), oxDJ-1 (-58%), p-TAU (-50%), pS935-LRRK2 (-58%), and pS129-αSyn (-78%), but had no significant effect on apoptotic markers pS63-c-JUN and CC3. Molecules. 2025 May 2;30(9):2034
PSEN1 I416T dopaminergic-like neurons (DALNs) 1 µM 4 days PF-475 significantly reduced the accumulation of iAβ (-44%), decreased oxDJ-1 (-72%), and reduced p-TAU (-73%). Additionally, it decreased pS935-LRRK2 (-60%) and pS129-αSyn (-48%), and reduced the expression of apoptotic markers pS63-c-JUN (-18%) and CC3 (-41%). Molecules. 2025 May 2;30(9):2034
DALNs (dopamine-like neurons) 1 µM 6 hours or 24 hours To evaluate the effect of PF-06447475 on ROT-induced apoptosis and autophagy. Results showed that PF-06447475 almost completely inhibited the phosphorylation of p-S935-LRRK2, reduced the number of CC3-positive cells, and decreased the accumulation of lysosomes. Int J Mol Sci. 2023 Oct 30;24(21):15744
SH-SY5Y cells 150 nM 6 weeks To investigate the effects of long-term LRRK2 kinase inhibition on LRRK2 protein levels and S935 phosphorylation. Results showed sustained reduction in LRRK2 protein levels and S935 phosphorylation. Mol Neurobiol. 2019 Aug;56(8):5273-5286
SH-SY5Y cells 150 nM various time periods To study the reversibility of LRRK2 kinase inhibition. Results showed complete recovery of S935 phosphorylation after inhibitor withdrawal, and full recovery of LRRK2 protein levels after 3 days. Mol Neurobiol. 2019 Aug;56(8):5273-5286

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Drosophila melanogaster Wild type (w[1118]) and TH > Lrrk2-RNAi transgenic flies Oral 0.05, 0.075, 0.1 µM 15 days To evaluate the effects of PF-475 on lifespan, locomotor activity, DAergic neuronal integrity, and lipid peroxidation in Drosophila melanogaster. Results showed PF-475 significantly prolonged lifespan, improved locomotor activity, and reduced lipid peroxidation. Neurochem Res. 2024 Sep;49(9):2440-2452
CD1 mice Moderate traumatic brain injury model Intraperitoneal injection 1, 2.5 and 5 mg/kg Once daily for 14 days PF-06447475 significantly reduced histological damage and behavioral disturbances, showing an antidepressant effect and restoring changes in the copper/glutamate/N-methyl-D-aspartic acid receptor (Cu/NMDAR) system. Cells. 2023 Mar 29;12(7):1040
Mice BALB/c mice Tail vein injection 10 mg/kg Single dose, 45 minutes Evaluate the effect of PF-06447475 on the biodistribution of [3H]LRRK2-IN-1 in mice, showing that 10 mg/kg PF-06447475 reduced the uptake of [3H]LRRK2-IN-1 by 54% in kidney and 62% in brain. Mol Imaging Biol. 2017 Dec;19(6):837-845
CD1 mice MPTP-induced Parkinson's disease model Intraperitoneal injection 2.5, 5, and 10 mg/kg Once daily for 7 days To evaluate the effect of PF-475 on MPTP-induced Parkinson's disease in the central nervous system and gastrointestinal system. Results showed that PF-475 reduced brain α-synuclein accumulation, modulated the mitophagy pathway, and decreased pro-inflammatory markers and α-synuclein aggregates in colonic tissues. iScience. 2024 Sep 16;27(10):110980
Male Sprague-Dawley rats Traumatic brain injury (TBI) model Intraperitoneal injection 3 mg/kg and 5 mg/kg Administered at 1 hour post-TBI PF-06447475 significantly reduced neuronal apoptosis, brain water content, and blood–brain barrier permeability at 12 h post-TBI and ameliorated neurological deficits at 72 h post-TBI. Front Cell Neurosci. 2018 Mar 1;12:51
Rats G2019S-LRRK2 transgenic rats and wild-type rats Oral gavage 30 mg/kg Twice daily for 4 weeks To evaluate the in vivo inhibitory effect of PF-06447475 on LRRK2 kinase activity and its neuroprotective effects against neurodegeneration. Results showed that PF-06447475 significantly mitigated α-synuclein-induced dopaminergic neurodegeneration and neuroinflammation, with no adverse pathological effects observed in the lung, kidney, or liver after 4 weeks of treatment. J Biol Chem. 2015 Aug 7;290(32):19433-44

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.28mL

0.66mL

0.33mL

16.38mL

3.28mL

1.64mL

32.75mL

6.55mL

3.28mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories